

1 Title page

2 **Title:** Development of interoperable, domain-specific extensions for the German Corona
3 Consensus (GECCO) COVID-19 research dataset using an interdisciplinary, consensus-based
4 workflow

5 **Authors:** Gregor Lichtner^{1,2,3}, Thomas Haese¹, Sally Brose⁴, Larissa Röhrig^{1,5}, Liudmila Lysyakova^{6,7}, Stefanie
6 Rudolph^{6,7}, Maria Uebe^{6,7}, Julian Sass¹, Alexander Bartschke¹, David Hillus⁸, Florian Kurth^{8,9}, Leif Erik
7 Sander⁸, Falk Eckart¹⁰, Nicole Toepfner¹⁰, Reinhard Berner¹⁰, Anna Frey¹¹, Marcus Dörr¹², Jörg Janne
8 Vehreschild^{13,14,15}, Christof von Kalle^{6,7}, Sylvia Thun¹

9 ¹ Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany

10 ² Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and
11 Humboldt-Universität zu Berlin, Institute of Medical Informatics, Berlin, Germany

12 ³ Universitätsmedizin Greifswald, Department of Anesthesia, Critical Care, Emergency and Pain
13 Medicine, Greifswald, Germany

14 ⁴ Robert Koch Institute, Department of Methodology and Research Infrastructure, Research Data
15 Management, Berlin, Germany

16 ⁵ National Association of Statutory Health Insurance Physicians ("Kassenärztliche
17 Bundesvereinigung"; KBV), Digitalization and IT, Department Interoperability, Berlin, Germany

18 ⁶ Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and
19 Humboldt-Universität zu Berlin, joint Charité and BIH Clinical Study Center, Berlin, Germany

20 ⁷ Berlin Institute of Health at Charité – Universitätsmedizin Berlin, joint Charité and BIH Clinical
21 Study Center, Berlin, Germany

22 ⁸ Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and
23 Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory Medicine,
24 Berlin, Germany

25 ⁹ University Medical Centre Hamburg-Eppendorf, Department of Tropical Medicine, Bernhard
26 Nocht Institute for Tropical Medicine and Department of Medicine I, Hamburg, Germany

27 ¹⁰ Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität
28 Dresden, Dresden, Germany

29 ¹¹ University Hospital of Würzburg, Medical Clinic and Policlinic I, Würzburg, Germany

30 ¹² Universitätsmedizin Greifswald, Department of Internal Medicine B, Greifswald, Germany

31 ¹³ Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

32 ¹⁴ German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany

33 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 ¹⁵ Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt,
Frankfurt am Main, Germany

35 Abstract

36 Background

37 The COVID-19 pandemic has spurred large-scale, inter-institutional research efforts. To enable these
38 efforts, researchers must agree on dataset definitions that not only cover all elements relevant to the
39 respective medical specialty but that are also syntactically and semantically interoperable. Following
40 such an effort, the German Corona Consensus (GECCO) dataset has been developed previously as a
41 harmonized, interoperable collection of the most relevant data elements for COVID-19-related patient
42 research. As GECCO has been developed as a compact core dataset across all medical fields, the
43 focused research within particular medical domains demands the definition of extension modules that
44 include those data elements that are most relevant to the research performed in these individual
45 medical specialties.

46 Objective

47 To (i) specify a workflow for the development of interoperable dataset definitions that involves a close
48 collaboration between medical experts and information scientists and to (ii) apply the workflow to
49 develop dataset definitions that include data elements most relevant to COVID-19-related patient
50 research in *immunization*, *pediatrics*, and *cardiology*.

51 Methods

52 We developed a workflow to create dataset definitions that are (i) content-wise as relevant as possible
53 to a specific field of study and (ii) universally usable across computer systems, institutions, and
54 countries, i.e., interoperable. We then gathered medical experts from three specialties (*immunization*,
55 *pediatrics*, and *cardiology*) to select data elements most relevant to COVID-19-related patient
56 research in the respective specialty. We mapped the data elements to international standardized
57 vocabularies and created data exchange specifications using HL7 FHIR. All steps were performed in
58 close interdisciplinary collaboration between medical domain experts and medical information
59 scientists. The profiles and vocabulary mappings were syntactically and semantically validated in a two-
60 stage process.

61 Results

62 We created GECCO extension modules for the *immunization*, *pediatrics*, and *cardiology* domains with
63 respect to the pandemic requests. The data elements included in each of these modules were selected
64 according to the here developed consensus-based workflow by medical experts from the respective
65 specialty to ensure that the contents are aligned with the respective research needs. We defined
66 dataset specifications for a total number of 48 (*immunization*), 150 (*pediatrics*), and 52 (*cardiology*)

67 data elements that complement the GECCO core dataset. We created and published implementation
68 guides and example implementations as well as dataset annotations for each extension module.

69 [Conclusions](#)

70 These here presented GECCO extension modules, which contain data elements most relevant to
71 COVID-19-related patient research in *immunization*, *pediatrics* and *cardiology*, were defined in an
72 interdisciplinary, iterative, consensus-based workflow that may serve as a blueprint for the
73 development of further dataset definitions. The GECCO extension modules provide a standardized and
74 harmonized definition of specialty-related datasets that can help to enable inter-institutional and
75 cross-country COVID-19 research in these specialties.

76

77 Keywords

78 - COVID-19

79 - Interoperability

80 - GECCO dataset

81 - FHIR

82 - Research dataset

83 - FAIR principles

84

85 Introduction

86 The COVID-19 pandemic has led to unprecedented strong efforts in connecting nationwide and
87 international research to help in managing the disease and its effects on public health. To enable
88 research across different health care providers, institutions or even countries, interoperability
89 between the medical data systems is essential [1]. Therefore, early in the pandemic, the German
90 Corona Consensus Dataset (GECCO) has been developed in a collaborative effort to provide a
91 standardized, unified core dataset for inter-institutional COVID-19-related patient research [2]. The
92 GECCO dataset specifies a set of 81 essential clinical data elements from 13 domains such as anamnesis
93 & risk factors, symptoms, and vital signs, that have been selected by expert committees from university
94 hospitals, professional associations, and research initiatives. Since its development, the GECCO dataset
95 has been implemented in a large number of institutions, most notably in virtually every German
96 university hospital, which now provides access to the GECCO dataset in the context of the German
97 COVID-19 Research Network of University Medicine (“Netzwerk Universitätsmedizin”) [3,4].

98 The GECCO dataset has been developed to contain as many relevant data elements as possible, but
99 few enough to keep the effort of implementing the dataset manageable. Therefore, the dataset
100 contains mostly data elements of general research interest, excluding data elements that are only of
101 interest for particular medical specialties or use cases. These data items are considered part of domain-
102 specific extension modules to the GECCO dataset, which are introduced in this article.

103 Thus, we here aimed to develop domain-specific extensions to the GECCO dataset that cover the most
104 relevant data elements for COVID-19-related patient research for the medical specialties of
105 *immunization, pediatrics, and cardiology*. To that end, we first developed a workflow that aims at
106 providing dataset definitions that (i) contain the most relevant data elements for the research aims of
107 the end users and (ii) that can be applied universally across institutions and countries. We then
108 followed that workflow with different groups of medical experts from different medical specialties to
109 define extension modules relevant for *immunization, pediatrics, and cardiology*.

110 These extension modules complement the GECCO core dataset and use the same international health
111 IT standards and terminologies as the GECCO dataset, such as the *Systematized Nomenclature of*
112 *Medicine - Clinical Terms* (SNOMED CT)[5] and *Logical Observation Identifiers Names and Codes*
113 (LOINC)[6,7] and the *Fast Healthcare Interoperability Resources* (FHIR)[8,9] standard. The extension
114 modules were developed in close alignment with the GECCO dataset to ensure interoperability and
115 compatibility with existing definitions.

116 We here describe the consensus-based data element selection and data format definition workflow
117 that we applied in close collaboration between medical experts from *immunology, pediatrics, and*

118 *cardiology* domains on the content definition side and medical information specialists and FHIR
119 developers on the technical side. This workflow may serve as a blueprint for further development of
120 consensus-based data set definitions.

121 [Methods](#)

122 [Workflow definition](#)

123 We aimed to develop a workflow to create dataset definitions that are (i) content-wise as relevant as
124 possible to a specific field of study and (ii) universally usable across computer systems, institutions,
125 and countries, i.e., interoperable. We based the specification of the workflow on our experience with
126 the definition of the German Corona Consensus (GECCO) dataset, where health professionals from 50
127 institutions (university hospitals, professional associations and other relevant organizations)
128 participated to define the most relevant data elements for general scope COVID-19-related research
129 [2]. To fulfil the first requirement (relevancy), we decided to leave the full responsibility of data
130 element selection to groups of medical professionals of the respective specialty, with only minimal
131 interference by the development team. We have deliberately left the exact process open of how the
132 group of medical experts may select the data elements (e.g., literature review, focus groups,
133 consensus-based processes) to allow maximal flexibility of the dataset definition workflow with
134 respect to the medical experts' values and preferences. To fulfil the second requirement
135 (interoperability), we adopted a model loosely based on Jacobsen's workflow for data FAIRification
136 [10], with mapping, quality assurance and publication steps as outlined in detail below.

137 [Selection of data items](#)

138 The content of the domain-specific research datasets was defined by medical domain experts in a
139 transparent workflow (Figure 1). The involvement of the medical domain experts as the end-users of
140 the data to be provided ensured that the contents of the datasets are aligned to the actual research
141 needs. In our project, the so-called subject- and organ-specific working groups of the national
142 pandemic cohort net (NAPKON) served as the domain-specific groups of medical experts. These groups
143 were established by voluntary association of medical experts from the respective medical specialty in
144 the context of the nationwide NAPKON project in Germany. Each of the subject- and organ-specific
145 working groups elected a board, and all communication between the dataset developers and the
146 working groups was organized and carried out via the working groups' board. In preparation for the
147 GECCO extension modules, we invited the subject- and organ-specific groups for *immunology*,
148 *pediatrics* and *cardiology* to provide up to 50 data elements with up to 10 response items each that
149 were, in the view of the medical experts, the most relevant data elements to patient-related COVID-
150 19 research in their medical specialty and that were not already included in the GECCO core dataset.

151 If necessary, more data items or response options could be provided in coordination with the
152 development team. The provided data items were then reviewed by the development team and a first
153 definition of the contents of the extension module was returned to the respective subject- and organ-
154 specific working group for approval or change requests. After approval by the subject- and organ-
155 specific working group, the definition of the extension module content was considered finalized.

156 [Development of the standardized data formats](#)

157 To map the data items selected by the subject- and organ-specific working groups to international
158 standard vocabularies, we performed a consensus-based mapping procedure, where every concept
159 was mapped to appropriate vocabularies SNOMED CT for general concepts [11], LOINC for
160 observations [7], *International Statistical Classification of Diseases and Related Health Problems, 10th*
161 *revision, German modification* (ICD-10-GM) for diagnoses [12], *Anatomical Therapeutic Chemical*
162 *Classification System* (ATC) for Germany for drugs and active ingredients [13], *Unified Code for Units*
163 *of Measure* (UCUM) for measurement units [14] by two medical information scientists independently.
164 Ambiguities and non-matching mappings were then discussed within the development team and in
165 close collaboration with the medical experts of the subject- and organ-specific working groups until
166 consensus was achieved. The data item-to-concept mappings were annotated on ART-DECOR, an
167 open-source collaboration platform for creating and maintaining dataset element descriptions [15].

168 As for the GECCO dataset, the format for data exchange was specified using HL7 FHIR resources. The
169 mapping of data items to FHIR resources was performed in an iterative, consensus-based workflow
170 among the development team. Wherever possible, published FHIR profiles from the GECCO dataset,
171 from the Medical Informatics Initiative (MII) [16] or the National Association of Statutory Health
172 Insurance Physicians (“Kassenärztliche Bundesvereinigung”; KBV) [17] – in this order of priority –
173 served as the base definition for the future extension module profiles.

174 The profiles and value sets were specified using the FHIR Shorthand (FSH) language (version 1.2.0) and
175 translated to Structure Definition JSON files using the HL7 FSH SUSHI software package (version 2.2.3)
176 [18,19]. We required that at least one exemplary instance be defined for every profile. Syntactic
177 validation of the profiles and value sets definitions was performed using the error-free conversion of
178 the FSH files to JSON using SUSHI and subsequent validation of each profile with their defined instances
179 using the HL7 FHIR validator as implemented in the FHIR Shorthand Validator Python package (version
180 0.2.2) [20]. After successful syntactic validation of a set of profiles, the profiles were subjected to a
181 two-stage review process as follows. First, the profiles and corresponding value sets and extensions
182 were internally reviewed for semantic appropriateness with the GECCO core developer (JS). After all
183 necessary changes and approval by the internal reviewer, the profiles were subjected to the second
184 review round by an external FHIR development expert. Subsequent to necessary corrections and

185 approval of the external reviewer, the respective profiles together with their value sets and optionally
186 extensions and code systems were considered finalized and published to the main branch of the git
187 repository.

188 The whole development process was performed collaboratively on GitHub. Syntactic validation of the
189 profiles was performed by continuous integration/continuous development (CI/CD) workflows
190 implemented as GitHub actions. Semantic validation during the internal and external review rounds
191 was performed using pull requests to two different git branches. After the final approval, profiles and
192 value sets were merged into the main branch of the extension module's repository, which served as
193 the publication branch of the respective module. Since then, maintenance requests and updates of the
194 extension modules are handled via GitHub issues. All kinds of relevant changes become a subject of
195 the internal review as defined above; major changes (e.g., non-technical corrections) are additionally
196 exposed to the external review.

197 Implementation guides were created for all three extension modules using the FHIR IG publisher tool
198 and a customized template for the implementation guide's HTML pages [21]. The implementation
199 guides are published to GitHub pages and remain automatically synchronized with the main branch of
200 the respective repository via CI/CD workflows.


201

202 Results

203 Dataset definition workflow

204 We developed an interdisciplinary, iterative, consensus-based workflow for the definition of domain-
205 specific COVID-19 research datasets based on two key requirements: The first key requirement for the
206 content of the datasets was that the content definition (i.e., selection of data elements) was to be
207 performed in full responsibility by a group of medical experts to ensure that the selected data elements
208 are truly those that are required in research of their respective medical specialty. The second key
209 requirement was to produce FAIR (Findable, Accessible, Interoperable, Reusable) digital assets [22]:
210 The dataset definitions shall be represented in FHIR profiles and implementation guides and these shall
211 be registered on open platforms (Findable), they shall be retrievable through open, free, standard
212 protocols (Accessible), they shall use only standard, international medical terminologies such as
213 SNOMED CT and LOINC (Interoperable) and they shall be released with rich usage guides and examples
214 (FHIR implementation guide) and under a permissive license (Reusable).

215 To fulfill these requirements, the dataset definition workflow consists of four phases: Content
216 definition, mapping, quality assurance and publication (Figure 1). In the content definition phase, a
217 group of medical experts from a particular medical specialty are approached by the development team
218 consisting of medical information specialists and asked to provide a list of the data elements that are
219 most relevant to patient-related COVID-19 research in their respective medical specialty. How the
220 medical expert group compiles the list in detail is left to their discretion (e.g., based on systematic
221 literature review, or Delphi consensus processes). The medical information scientists only review the
222 provided lists for consistency and redundancy and compile the final content definition in agreement
223 with the medical experts group. In the mapping phase, all data elements are then mapped to
224 international terminologies in consultation with the group of medical experts. Based on these a logical
225 model and the mappings of data elements to FHIR resources are established. In the quality assurance
226 phase, the FHIR specifications are syntactically validated using automated software tools and then
227 subjected to a two-staged review process with two individual data interoperability and harmonization
228 experts to validate the specifications semantically, i.e., validate that the data elements defined by the
229 group of medical experts are appropriately mapped to international standards. After any required
230 changes, the logical model and the FHIR implementation guide are published openly accessible to the
231 research community in repositories that fulfill the FAIR criteria as closely as possible, such as ART-
232 DECOR[15] for logical models and GitHub or the FHIR Implementation Guide registry for the
233 implementation guide[23].



234
 235 *Figure 1 Flowchart of the consensus-based, interdisciplinary dataset definition and mapping workflow*
 236 *for the domain-specific COVID-19 research datasets.*

237
 238 **Datasets contents**

239 **Groups of medical experts**
 240 In the context of the national pandemic cohort net (“Nationales Pandemie Kohorten Netz”; NAPKON)
 241 project of the German COVID-19 Research Network of University Medicine [24], so-called subject- and
 242 organ-specific working groups were established by the voluntary association of medical experts from
 243 different medical specialties. In preparation for the domain-specific dataset definitions that extend the
 244 GECCO core dataset, the working groups for *immunology*, *pediatrics*, and *cardiology* were invited by
 245 the dataset development group to provide up to 50 data elements with up to 10 response items each
 246 that were of particular interest to their field concerning patient-related COVID-19 research and that
 247 were not already included in the GECCO core dataset. For the *immunization* dataset definition,
 248 physicians from the “NUM-COVIM” study for the determination and use of SARS-CoV-2 immunity [25–
 249 27] assumed the role of the organ-specific working group, as no such working group had been
 250 established previously.

251

252 [Overview](#)

253 The domain-specific dataset definitions developed in this work extend the GECCO core dataset by a
 254 total number of 48 data items for the *immunization* extension module, 150 for the *pediatrics* extension
 255 module, and 52 for the *cardiology* extension module. These data items have been collected via an
 256 iterative consensus-based approach from the respective subject- and organ-specific working groups
 257 and belonging to 10 of the 13 data categories of the GECCO dataset (Table 1). Data elements and
 258 number of items for each individual extension module are shown in Table 2, Table 3, and Table 4. The
 259 full lists of items are shown in the supplementary tables 1, 2, and 3.

GECCO Data Category	GECCO Extension Module		
	Immunization	Pediatrics	Cardiology
Anamnesis & Risk factors	13	21	6
Complications	24	47	7
Demographics	-	6	-
Epidemiological factors	-	-	-
Imaging	-	2	36
Laboratory values	1	27	2
Medication	1	35	1
Onset of illness & admission	6	2	-
Outcome at discharge	-	-	-
Study enrollment & Inclusion criteria	-	-	-
Symptoms	-	9	-
Therapy	2	1	-
Vital signs	1	-	-
Total items	48	150	52

260 *Table 1 Number of data items per GECCO dataset category for each extension module.*

261 All data items were mapped to the appropriate FHIR resources Observation, Condition, Procedure,
 262 MedicationStatement, Encounter, Questionnaire, QuestionnaireResponse, Immunization,
 263 ImagingStudy, List, and Specimen, and 26, 14, and 18 profiles (25, 17, and 12 value sets) were created
 264 for the *immunization*, *pediatrics*, and *cardiology* extension module, respectively. The data items that
 265 were already part of the GECCO dataset and that were not removed during the data selection step
 266 were taken over from GECCO and referenced as such in the implementation guides.

267 The implementation guides for the three extension module have been published on GitHub pages [28–
 268 30]. The source FHIR ShortHand (FSH) files have been published on GitHub [31–33]. Logical models and
 269 dataset descriptions are hosted on ART-DECOR, an open collaboration platform for modelling dataset
 270 definitions and their descriptions and terminology bindings [34–36].

271

Category	Data Element	FHIR Resource	# items
Anamnesis	Chemotherapy	Procedure	1
	Immunosuppressive therapy	Procedure	1
	Regular Alcohol Intake	Observation	2
COVID-19 infection & treatment	Disease course	Encounter, Procedure	5
	SARS-CoV-2 infection	Condition	1
	SARS-CoV-2 variant	Observation	1
Immunization	Contraindications to immunization	Immunization	2
	Immunizations performed	Immunization	3
	Reason for immunization	Immunization	5
	Willingness to receive additional immunization doses	Observation	1
Immunization reactions	Analgesic or antipyretic drug intake	MedicationStatement	1
	Body temperature	Observation	1
	Complications after immunization	Observation	5
	Medical treatment for adverse reactions	Encounter	3
	Symptoms after Vaccination	Condition	16
Total			48

272 *Table 2 Types of data elements in the immunization extension module extending the GECCO core*
 273 *dataset. Shown are the data elements and the FHIR resource they have been mapped to, as well as the*
 274 *number of items for each data element (i.e., different response options).*

Category	Data Element	FHIR Resource	# items
Complications	Complications to COVID-19	Condition	47
Demographics	Body measures	Observation	6
Imaging	Echocardiography	Procedure, Imaging Study	1
	PET-CT	Procedure, Imaging Study	1
Immunization	Immunizations performed	Immunization	2
Laboratory values	Laboratory values	Observation	27
Medical history	Chronic Hematologic Diseases	Condition	8
	Chronic Kidney Diseases	Condition	2
	Congenital Disease	Condition	1
	Gastrointestinal Diseases	Condition	6
	Medical History Stem Cells Transplant	Condition	2
Medication	Medication	MedicationStatement, List	35
Symptoms	COVID-19 Symptoms	Condition	9
Therapy	Hospitalization	Observation	2
	Thoracic Drainage	Procedure	1
Total			150

275 *Table 3 Types of data elements in the pediatrics extension module extending the GECCO core dataset.*
 276 *Shown are the data elements and the FHIR resource they have been mapped to, as well as the number*
 277 *of items for each data element (i.e., different response options).*

278

Category	Data Element	FHIR Resource	# items
Anamnesis	Chronic cardiologic diseases	Condition	6
COVID-19-related complications	Cardiologic complications of COVID-19	Condition	7
Echocardiography	Echocardiography findings	Observation	20
	Echocardiography procedure	Procedure	3
Electrocardiography	Electrocardiography findings	Observation	11
	Electrocardiography procedure	Procedure	2
Laboratory Values	Laboratory values	Observation	2
Medication	Angiotensin receptor antagonist	MedicationStatement	1
Total			52

279 *Table 4 Types of data elements in the cardiology extension module extending the GECCO core dataset.*
280 *Shown are the data elements and the FHIR resource they have been mapped to, as well as the number*
281 *of items for each data element (i.e., different response options).*

282 Discussion

283 We here present an interdisciplinary, iterative, consensus-based workflow to the definition of research
284 datasets, focusing on creating datasets with the most relevant data elements for a particular field of
285 study and on creating universally usable datasets according to the FAIR principles [22]. We applied the
286 workflow to develop three GECCO extension modules that contain data items relevant for COVID-19-
287 related patient research in the *immunization*, *pediatrics*, and *cardiology* fields. These extension
288 modules complement the GECCO core dataset for domain-specified research. The data items are
289 represented in HL7 FHIR profiles and use international terminologies, to ensure a harmonized,
290 standardized, and interoperable dataset definition for these medical domains. The provision of data
291 according to the extension modules introduced in this article will enable cross-institutional and cross-
292 country data collection and collaborative research with a particular focus in *immunization*, *pediatrics*,
293 and *cardiology*.

294 We have specified and implemented an interdisciplinary, iterative, consensus-based workflow for the
295 selection of data items and the development of the dataset definition. The close collaboration and the
296 constant feedback loops with domain experts from the respective medical specialties right from the
297 beginning of the project, as performed here, are key for the successful development of a useful dataset
298 definition. Indeed, since the selection of relevant data items was driven by the end-users of the
299 dataset, who are the researchers that later will be using the data for their specialized areas of research,
300 the semantic usability of the datasets is guaranteed. Likewise, having medical information specialists
301 develop the formal dataset specification ensures technical interoperability and usability of the dataset
302 definition.

303 Next to the successful development of dataset definitions, several factors determine a successful
304 deployment or use of the developed extension modules [37]. First and most importantly clear and
305 concise documentation of how to implement and provide data using the dataset definition is required.
306 For FHIR-based dataset definitions, so-called implementation guides are used to provide both a
307 narrative overview as well as technical details on the dataset definition [38]. Thus, we have created
308 and published implementation guides for each of the here-developed extension modules. Second, the
309 example implementations of the extension modules serve as a blueprint for developers and data
310 engineers who implement the extension modules for their clinical databases. From our experience
311 with the implementation of the GECCO dataset, well-defined example data items may be of equal if
312 not higher importance than the technical description of the dataset specification, as developers and
313 engineers tend to use the examples as blueprints for their implementation. Thus, we equipped every
314 FHIR profile defined in the extension modules with at least one example. These examples are
315 incorporated and issued within the implementation guides of the modules. Specifically, we aimed to

316 provide one example for each different category of response option per profile. Thirdly, the actual
317 implementation of the extension modules should be part of follow-up infrastructure projects to supply
318 funding and resources for filling the dataset definition with actual data. For the GECCO dataset, this is
319 ensured by follow-up projects of the German COVID-19 Research Network of University Medicine
320 (“Netzwerk Universitätsmedizin”), such as CODEX+, which includes several implementation tasks that
321 are actively using the GECCO dataset items [39] and further projects [40–43]. Fourth, once the dataset
322 definitions are implemented and leveraged in use cases, additional demands to the dataset are likely
323 raised or issues with existing definitions are revealed. The maintenance of existing definitions (e.g.,
324 performing technical corrections or even evolving the definitions or adding new items) is, therefore,
325 necessary and must be organized and funded. Last, successful use of the extension modules is also
326 highly dependent on the degree of interoperability of the dataset definitions in the first place [1,44,45].
327 For example, the use of questionnaires to assess certain features is common in clinical research.
328 However, depending on the exact wording of the question and the number and wording of response
329 options, results from different studies might not be directly comparable although they assessed the
330 same features, as the questions and response options differ between studies. In the presented
331 extension modules, several items were at first specified in a questionnaire-like fashion and direct
332 implementation of these as Questionnaire resources in FHIR would have limited the applicability of
333 such data elements, especially when aiming to map these elements from an electronic health records
334 (EHR) system. In these cases, we revised the data elements specification to use interoperable concepts
335 rather than questions. Here, repeated consultation with and final approval of the group of medical
336 experts was key to be able to convert questions into interoperable concepts that convey the same
337 information as intended by the content definition of the group of medical experts. In general, we
338 recommend not to use Questionnaire/QuestionnaireResponse FHIR profiles in cases where the
339 information to be represented can be modeled using more general, interoperable concepts and FHIR
340 resources.

341 Conclusion

342 We here introduce the development workflow and the resulting dataset definitions for GECCO
343 extension modules for the *immunization*, *pediatrics*, and *cardiology* domains. We have defined and
344 implemented a workflow in which interdisciplinary teams of medical domain experts, medical
345 information scientists and FHIR developers closely collaborate in an iterative, consensus-based fashion
346 for the successful development of useful and interoperable dataset definitions. This workflow may
347 serve as a blueprint for further dataset definition projects, such as further dataset definitions for
348 extending the GECCO core dataset. The extension modules described in this work have been validated
349 and published. Their implementation and active use are anticipated in the context of current
350 nationwide COVID-19 research networks in Germany.

351 Acknowledgements

352 The NAPKON (“Nationales Pandemie Kohorten Netz”, German National Pandemic Cohort Network)
353 project is funded under a scheme issued by the Network of University Medicine (Nationales
354 Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and
355 Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)) grant number
356 01KX2021. The funding body did not take a role in the design of the study, development of the dataset
357 or in the writing of the manuscript.

358 We thank Yannick Börner for his valuable contribution to the definition of the FHIR profiles. We thank
359 all members of the subject- and organ-specific working groups.

360

361 Conflict of interests

362 The authors declare that they have no competing interests.

363 Data Availability

364 The implementation guides for the three extension modules have been published on GitHub pages
365 [28–30]. The source FHIR ShortHand (FSH) files have been published on GitHub [31–33]. Dataset
366 descriptions can be found on ART-DECOR [34–36]

367 Authors’ contributions

368 All authors contributed to the development of the extension modules. GL, TH, SB, LR, JS, AB, ST
369 performed terminology mapping, FHIR profiling and critical review of the concept and resource
370 mappings. TH, SB, LR defined the datasets in ART-DECOR. DH, FK, LES, FB, FE, NT, RB, AF, MD developed
371 and compiled the list of data items for the datasets. SR, LL and MU coordinated the project and the
372 consensus finding process within and between working groups. JJV, CvK, ST conceived the work. GL
373 drafted the manuscript. All authors read and approved the final manuscript.

374

375 References

- 376 1. Lehne M, Sass J, Essenwanger A, Schepers J, Thun S. Why digital medicine depends on
377 interoperability. *Npj Digit Med Nature Publishing Group*; 2019 Aug 20;2(1):1–5. doi:
378 10.1038/s41746-019-0158-1
- 379 2. Sass J, Bartschke A, Lehne M, Essenwanger A, Rinaldi E, Rudolph S, Heitmann KU, Vehreschild JJ,
380 von Kalle C, Thun S. The German Corona Consensus Dataset (GECCO): a standardized dataset for
381 COVID-19 research in university medicine and beyond. *BMC Med Inform Decis Mak* 2020 Dec
382 21;20(1):341. doi: 10.1186/s12911-020-01374-w
- 383 3. Gruendner J, Deppenwiese N, Folz M, Köhler T, Kroll B, Prokosch H-U, Rosenau L, Rühle M, Scheidl
384 M-A, Schüttler C, Sedlmayr B, Twrdik A, Kiel A, Majeed RW. The Architecture of a Feasibility Query
385 Portal for Distributed COVID-19 Fast Healthcare Interoperability Resources (FHIR) Patient Data
386 Repositories: Design and Implementation Study. *JMIR Med Inform* 2022 May 25;10(5):e36709.
387 doi: 10.2196/36709
- 388 4. Sedlmayr B, Sedlmayr M, Kroll B, Prokosch H-U, Gruendner J, Schüttler C. Improving COVID-19
389 Research of University Hospitals in Germany: Formative Usability Evaluation of the CODEX
390 Feasibility Portal. *Appl Clin Inform Georg Thieme Verlag KG*; 2022 Mar;13(2):400–409. doi:
391 10.1055/s-0042-1744549
- 392 5. Millar J. The Need for a Global Language – SNOMED CT Introduction. *Nurs Inform* 2016 IOS Press;
393 2016;683–685. doi: 10.3233/978-1-61499-658-3-683
- 394 6. Fiebeck J, Gietzelt M, Ballout S, Christmann M, Fradziak M, Laser H, Ruppel J, Schönfeld N,
395 Teppner S, Gerbel S. Implementing LOINC - Current Status and Ongoing Work at a Medical
396 University. *Stud Health Technol Inform* 2019 Sep 3;267:59–65. PMID:31483255
- 397 7. McDonald CJ, Huff SM, Suico JG, Hill G, Leavelle D, Aller R, Forrey A, Mercer K, DeMoor G, Hook
398 J, Williams W, Case J, Maloney P, for the Laboratory LOINC Developers. LOINC, a Universal
399 Standard for Identifying Laboratory Observations: A 5-Year Update. *Clin Chem* 2003 Apr
400 1;49(4):624–633. doi: 10.1373/49.4.624
- 401 8. Lehne M, Luijten S, Vom Felde Genannt Imbusch P, Thun S. The Use of FHIR in Digital Health - A
402 Review of the Scientific Literature. *Stud Health Technol Inform* 2019 Sep 3;267:52–58.
403 PMID:31483254
- 404 9. Vorisek CN, Lehne M, Klopfenstein SAI, Mayer PJ, Bartschke A, Haese T, Thun S. Fast Healthcare
405 Interoperability Resources (FHIR) for Interoperability in Health Research: Systematic Review.
406 *JMIR Med Inform* 2022 Jul 19;10(7):e35724. doi: 10.2196/35724
- 407 10. Jacobsen A, Kaliyaperumal R, da Silva Santos LOB, Mons B, Schultes E, Roos M, Thompson M. A
408 Generic Workflow for the Data FAIRification Process. *Data Intell* 2020 Jan 1;2(1–2):56–65. doi:
409 10.1162/dint_a_00028
- 410 11. SNOMED CT. SNOMED. Available from: <https://www.snomed.org/> [accessed Mar 16, 2022]
- 411 12. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). ICD-10-GM. Available from:
412 https://www.bfarm.de/EN/Code-systems/Classifications/ICD/ICD-10-GM/_node.html [accessed
413 Mar 16, 2022]

- 414 13. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). ATC. Available from:
415 https://www.bfarm.de/DE/Kodiersysteme/Klassifikationen/ATC/_node.html [accessed Mar 16,
416 2022]
- 417 14. The Unified Code for Units of Measure. Available from: <https://ucum.org/trac> [accessed Mar 16,
418 2022]
- 419 15. art-decor.org. Available from: https://www.art-decor.org/mediawiki/index.php/Main_Page
420 [accessed Mar 16, 2022]
- 421 16. Medizininformatik Initiative - SIMPLIFIER.NET. Available from:
422 <https://simplifier.net/organization/koordinationsstellemii> [accessed Mar 15, 2022]
- 423 17. Kassenärztliche Bundesvereinigung (KBV) - SIMPLIFIER.NET. Available from:
424 <https://simplifier.net/organization/kassenrztlichebundesvereinigungkbv> [accessed Mar 15,
425 2022]
- 426 18. FHIR Shorthand. Available from: <http://hl7.org/fhir/uv/shorthand/> [accessed Apr 25, 2022]
- 427 19. SUSHI Unshortens Short Hand Inputs. 2022. Available from: <https://github.com/FHIR/sushi>
428 [accessed Apr 25, 2022]
- 429 20. Lichtner G. FHIR Shorthand Validator. 2021. Available from: [https://github.com/glichtner/fsh-](https://github.com/glichtner/fsh-validator)
430 [validator](https://github.com/glichtner/fsh-validator) [accessed Mar 15, 2022]
- 431 21. napkon-module-template. 2022. Available from: [https://github.com/BIH-CEI/napkon-module-](https://github.com/BIH-CEI/napkon-module-template)
432 [template](https://github.com/BIH-CEI/napkon-module-template) [accessed Mar 15, 2022]
- 433 22. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten
434 J-W, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O,
435 Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJG, Groth P, Goble C, Grethe JS,
436 Heringa J, 't Hoen PAC, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL,
437 Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone S-A, Schultes E, Sengstag T, Slater T,
438 Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A,
439 Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data
440 management and stewardship. *Sci Data Nature Publishing Group*; 2016 Mar 15;3(1):160018. doi:
441 10.1038/sdata.2016.18
- 442 23. Implementation Guide Registry. Available from: <http://fhir.org/guides/registry/> [accessed Nov 3,
443 2022]
- 444 24. Schons M, Pilgram L, Reese J-P, Stecher M, Anton G, Appel KS, Bahmer T, Bartschke A,
445 Bellinghausen C, Bernemann I, Brechtel M, Brinkmann F, Brünn C, Dhillon C, Fiessler C, Geisler R,
446 Hamelmann E, Hansch S, Hanses F, Hanß S, Herold S, Heyder R, Hofmann A-L, Hopff SM, Horn A,
447 Jakob C, Jiru-Hillmann S, Keil T, Khodamoradi Y, Kohls M, Kraus M, Krefting D, Kunze S, Kurth F,
448 Lieb W, Lippert LJ, Lorbeer R, Lorenz-Depiereux B, Maetzler C, Miljukov O, Nauck M, Pape D,
449 Püntmann V, Reinke L, Römmele C, Rudolph S, Sass J, Schäfer C, Schaller J, Schattschneider M,
450 Scheer C, Scherer M, Schmidt S, Schmidt J, Seibel K, Stahl D, Steinbeis F, Störk S, Tauchert M,
451 Tebbe JJ, Thibeault C, Toepfner N, Ungethüm K, Vadasz I, Valentin H, Wiedmann S, Zoller T, Nagel
452 E, Krawczak M, von Kalle C, Illig T, Schreiber S, Witzenrath M, Heuschmann P, Vehreschild JJ,
453 NAPKON Research Group. The German National Pandemic Cohort Network (NAPKON): rationale,
454 study design and baseline characteristics. *Eur J Epidemiol* 2022 Aug 1;37(8):849–870. doi:
455 10.1007/s10654-022-00896-z

- 456 25. Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig ET, Lippert
457 LJ, Tscheak P, Schmidt ML, Riege J, Solarek A, Kalle C von, Dang-Heine C, Gruell H, Kopankiewicz
458 P, Suttorp N, Drosten C, Bias H, Seybold J, Al-Rim B, Bardtke L, Beheim-Schwarzbach JI, Behn K,
459 Bergfeld L, Bethke N, Bleicker T, Briesemeister D, Brumhard S, Conrad C, Dieckmann S, Frey D,
460 Gabelich J-A, Georg P, Gläser U, Hasler L, Hetey A, Hiller AL, Horn A, Hülso C, Kegel L, Koch W,
461 Krannich A, Kroneberg P, Lisy M, Mackeldanz P, Maeß B, Münn F, Olk N, Peiser C, Pohl K, Hermel
462 A, Rönnefarth M, Rubisch C, Rezza AS, Schellenberger I, Schenkel V, Schlesinger J, Schmidt S,
463 Schwanitz G, Sinnigen A-S, Stubbemann P, Tesch J, Treue D, Wendisch D, Zvorc S, Klein F, Kurth
464 F, Corman VM, Sander LE. Safety, reactogenicity, and immunogenicity of homologous and
465 heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective
466 cohort study. *Lancet Respir Med Elsevier*; 2021 Nov 1;9(11):1255–1265. PMID:34391547
- 467 26. Tober-Lau P, Schwarz T, Vanshylla K, Hillus D, Gruell H, Suttorp N, Landgraf I, Kappert K, Seybold
468 J, Drosten C, Klein F, Kurth F, Sander LE, Corman VM. Long-term immunogenicity of BNT162b2
469 vaccination in older people and younger health-care workers. *Lancet Respir Med Elsevier*; 2021
470 Nov 1;9(11):e104–e105. PMID:34687656
- 471 27. NUM-COVIM study. Available from: <https://covim-netzwerk.de/> [accessed Mar 16, 2022]
- 472 28. NAPKON Cardiology Module Implementation Guide. Available from: [https://bih-
473 cei.github.io/napkon-cardiology/](https://bih-cei.github.io/napkon-cardiology/) [accessed Mar 15, 2022]
- 474 29. NAPKON Pediatrics Module Implementation Guide. Available from: [https://bih-
475 cei.github.io/napkon-pediatrics/](https://bih-cei.github.io/napkon-pediatrics/) [accessed Mar 15, 2022]
- 476 30. NAPKON Vaccination Module Implementation Guide. Available from: [https://bih-
477 cei.github.io/napkon-vaccination/](https://bih-cei.github.io/napkon-vaccination/) [accessed Mar 15, 2022]
- 478 31. NAPKON Cardiology Module. 2022. Available from: [https://github.com/BIH-CEI/napkon-
479 cardiology](https://github.com/BIH-CEI/napkon-cardiology) [accessed Mar 15, 2022]
- 480 32. NAPKON Pediatrics Module. 2022. Available from: [https://github.com/BIH-CEI/napkon-
481 pediatrics](https://github.com/BIH-CEI/napkon-pediatrics) [accessed Mar 15, 2022]
- 482 33. NAPKON Vaccination Module. 2022. Available from: [https://github.com/BIH-CEI/napkon-
483 vaccination](https://github.com/BIH-CEI/napkon-vaccination) [accessed Mar 15, 2022]
- 484 34. ART-DECOR: NAPKON Cardiology Module. Available from: [https://art-decor.org/art-
485 decor/decor-datasets--covid19f-
486 ?id=2.16.840.1.113883.3.1937.777.53.1.2&effectiveDate=2020-08-
487 12T00%3A00%3A00&conceptId=2.16.840.1.113883.3.1937.777.53.2.250&conceptEffectiveDat
488 e=2021-02-16T13%3A25%3A43&language=en-US](https://art-decor.org/art-decor/decor-datasets--covid19f-?id=2.16.840.1.113883.3.1937.777.53.1.2&effectiveDate=2020-08-12T00%3A00%3A00&conceptId=2.16.840.1.113883.3.1937.777.53.2.250&conceptEffectiveDate=2021-02-16T13%3A25%3A43&language=en-US) [accessed Mar 16, 2022]
- 489 35. ART-DECOR: NAPKON Pediatrics Module. Available from: [https://art-decor.org/art-decor/decor-
490 datasets--covid19f-?id=2.16.840.1.113883.3.1937.777.53.1.2&effectiveDate=2020-08-
491 12T00%3A00%3A00&conceptId=2.16.840.1.113883.3.1937.777.53.2.453&conceptEffectiveDat
492 e=2021-08-25T12%3A45%3A26&language=en-US](https://art-decor.org/art-decor/decor-datasets--covid19f-?id=2.16.840.1.113883.3.1937.777.53.1.2&effectiveDate=2020-08-12T00%3A00%3A00&conceptId=2.16.840.1.113883.3.1937.777.53.2.453&conceptEffectiveDate=2021-08-25T12%3A45%3A26&language=en-US) [accessed Mar 16, 2022]
- 493 36. ART-DECOR: NAPKON Vaccination Module. Available from: [https://art-decor.org/art-
494 decor/decor-datasets--covid19f-
495 ?id=2.16.840.1.113883.3.1937.777.53.1.2&effectiveDate=2020-08-
496 12T00%3A00%3A00&conceptId=2.16.840.1.113883.3.1937.777.53.2.453&conceptEffectiveDat
497 e=2021-08-25T12%3A45%3A26&language=en-US](https://art-decor.org/art-decor/decor-datasets--covid19f-?id=2.16.840.1.113883.3.1937.777.53.1.2&effectiveDate=2020-08-12T00%3A00%3A00&conceptId=2.16.840.1.113883.3.1937.777.53.2.453&conceptEffectiveDate=2021-08-25T12%3A45%3A26&language=en-US) [accessed Mar 16, 2022]

- 498 37. Kush RD, Warzel D, Kush MA, Sherman A, Navarro EA, Fitzmartin R, Pétavy F, Galvez J, Becnel LB,
499 Zhou FL, Harmon N, Jauregui B, Jackson T, Hudson L. FAIR data sharing: The roles of common
500 data elements and harmonization. *J Biomed Inform* 2020 Jul 1;107:103421. doi:
501 10.1016/j.jbi.2020.103421
- 502 38. Shivers J, Amlung J, Ratanaprayul N, Rhodes B, Biondich P. Enhancing narrative clinical guidance
503 with computer-readable artifacts: Authoring FHIR implementation guides based on WHO
504 recommendations. *J Biomed Inform* 2021 Aug 25;122:103891. PMID:34450285
- 505 39. Lichtner G, Jurth C, Alper BS, Spies C, Boeker M, Meerpohl JJ, Dincklage F von. Representation of
506 evidence-based clinical practice guideline recommendations on FHIR. medRxiv; 2022. p.
507 2022.05.16.22275120. doi: 10.1101/2022.05.16.22275120
- 508 40. Rinaldi E, Stellmach C, Rajkumar NMR, Carocchia N, Dellacasa C, Giannella M, Guedes M,
509 Mirandola M, Scipione G, Tacconelli E, Thun S. Harmonization and standardization of data for a
510 pan-European cohort on SARS- CoV-2 pandemic. *Npj Digit Med* Nature Publishing Group; 2022
511 Jun 14;5(1):1–13. doi: 10.1038/s41746-022-00620-x
- 512 41. Kapsner LA, Kampf MO, Seuchter SA, Gruendner J, Gulden C, Mate S, Mang JM, Schüttler C,
513 Deppenwiese N, Krause L, Zöller D, Balig J, Fuchs T, Fischer P, Haverkamp C, Holderried M, Mayer
514 G, Stenzhorn H, Stolnicu A, Storck M, Storf H, Zohner J, Kohlbacher O, Strzelczyk A, Schüttler J,
515 Acker T, Boeker M, Kaisers UX, Kestler HA, Prokosch H-U. Reduced Rate of Inpatient Hospital
516 Admissions in 18 German University Hospitals During the COVID-19 Lockdown. *Front Public*
517 *Health* 2021;8. Available from:
518 <https://www.frontiersin.org/articles/10.3389/fpubh.2020.594117> [accessed Oct 27, 2022]
- 519 42. Horn A, Krist L, Lieb W, Montellano FA, Kohls M, Haas K, Gelbrich G, Bolay-Gehrig SJ, Morbach C,
520 Reese JP, Störk S, Fricke J, Zoller T, Schmidt S, Triller P, Kretzler L, Rönnefarth M, Von Kalle C,
521 Willich SN, Kurth F, Steinbeis F, Witzenrath M, Bahmer T, Hermes A, Krawczak M, Reinke L,
522 Maetzler C, Franzenburg J, Enderle J, Flinspach A, Vehreschild J, Schons M, Illig T, Anton G,
523 Ungethüm K, Finkenber BC, Gehrig MT, Savaskan N, Heuschmann PU, Keil T, Schreiber S. Long-
524 term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design
525 and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform
526 (POP). *Infection* 2021 Dec 1;49(6):1277–1287. doi: 10.1007/s15010-021-01707-5
- 527 43. Prokosch H-U, Bahls T, Bialke M, Eils J, rgen, Fegeler C, Gruendner J, Haarbrandt B, Hampf C,
528 Hoffmann W, Hund H, Kampf M, Kapsner LA, Kasprzak P, Kohlbacher O, Krefting D, Mang JM,
529 Marschollek M, Mate S, Mü, Ller A, Prasser F, Sass J, Semler S, Stenzhorn H, Thun S, Zenker
530 S, Eils R. The COVID-19 Data Exchange Platform of the German University Medicine. *Chall Trust*
531 *AI Added-Value Health IOS Press*; 2022;674–678. doi: 10.3233/SHTI220554
- 532 44. Perlin JB. Health Information Technology Interoperability and Use for Better Care and Evidence.
533 *JAMA* 2016 Oct 25;316(16):1667–1668. doi: 10.1001/jama.2016.12337
- 534 45. Cutillo CM, Sharma KR, Foschini L, Kundu S, Mackintosh M, Mandl KD. Machine intelligence in
535 healthcare—perspectives on trustworthiness, explainability, usability, and transparency. *Npj*
536 *Digit Med* Nature Publishing Group; 2020 Mar 26;3(1):1–5. doi: 10.1038/s41746-020-0254-2

537

538

539 Supplementary Appendix

540 The following tables show the data items that are included in the immunization extension module
541 (Table S 1), the pediatrics extension module (Table S 2), and the cardiology extension module (Table S
542 3). Note that these tables list only the data items of the extension modules that are not included in the
543 GECCO core dataset and that the complete dataset definition for each specialty consists of the GECCO
544 core dataset together with the data items of the extension module.

545 GECCO Immunization extension module

Category	Data Element	FHIR Resource	Item
Anamnesis	Chemotherapy	Procedure	Chemotherapy
	Immunosuppressive therapy	Procedure	Immunosuppressive therapy
	Regular Alcohol Intake	Observation	Frequency
Quantity			
COVID-19 infection & treatment	Disease course	Encounter, Procedure	No symptoms
			Treated at home
			Treated at hospital with oxygen therapy
			Treated at hospital without oxygen therapy
	Treated at intensive care unit		
SARS-CoV-2 infection	Condition	SARS-CoV-2 infection	
SARS-CoV-2 variant	Observation	SARS-CoV-2 variant	
Immunization	Contraindications to immunization	Immunization	Allergy
			Pregnancy
	Immunizations performed	Immunization	Date
			Lot number
			Type
	Reason for immunization	Immunization	Everybody gets vaccinated
			Protection of private environment from infection/disease
Protection of themself from infection/disease			
Protection of work environment from infection/disease			
Worrying about disadvantages			
Willingness to receive additional immunization doses	Observation	Willingness to receive additional immunization doses	
Immunization reactions	Analgesic or antipyretic drug intake	MedicationStatement	Analgesic or antipyretic drug intake
	Body temperature	Observation	Body temperature after vaccination
			Allergic reaction after immunization
			Injection site erythema
			Injection site pain at rest
			Injection site pain during pressure/movement
	Injection site swelling		
	Medical treatment for adverse reactions	Encounter	Ambulatory
Inpatient			
No treatment			
Symptoms after Vaccination	Condition	Chill	

			Diarrhea
			Difficulty breathing
			Dyspnea
			Exhaustion
			Fatigue
			Feeling feverish
			Fever
			Fever with chills
			Joint pain
			Liquid stool
			Loose stool
			Muscle pain
			Nausea
			Soft stool
			Vomiting symptom

546 *Table S 1 Data items in the immunization extension module extending the GECCO core dataset. Shown*
 547 *are the data elements and the FHIR resource they have been mapped to, as well as the items for each*
 548 *data element (i.e., different response options).*

549

550 **GECCO Pediatrics extension module**

Category	Data Element	FHIR Resource	Item
Complications	Complications to COVID-19	Condition	Anemia
			Arterial aneurysm
			Ascites
			Aspergillosis
			Bacterial arthritis
			Bacterial endocarditis
			Bacterial meningitis
			Bacterial osteomyelitis
			Bronchiolitis
			Bronchitis
			Chlamydial infection
			Chronic fatigue syndrome
			Colitis
			Disease caused by Adenovirus
			Disease caused by Coronaviridae
			Disease caused by Human bocavirus
			Disease caused by Rhinovirus
			Disorder of liver
			Haemophilus influenzae infection
			Human metapneumovirus infection
Ileitis			

			Infection caused by Candida albicans
			Infection caused by Escherichia coli
			Infection caused by Klebsiella
			Infection caused by Pseudomonas aeruginosa
			Infection caused by Staphylococcus aureus
			Infection caused by Streptococcus viridans group
			Infection caused by enterococcus
			Infection of bloodstream
			Influenza
			Invasive Group A beta-hemolytic streptococcal disease
			Invasive Streptococcus pneumoniae disease
			Legionella infection
			Meningococcal infectious disease
			Mycoplasma infection
			Organic mental disorder
			Parainfluenza
			Peritonitis
			Pertussis
			Post-acute COVID-19
			Procedure needed Where Associated procedure = Resuscitation
			Pyelonephritis
			Respiratory syncytial virus infection
			Seizure disorder
			Streptococcus agalactiae infection
			Streptococcus pyogenes infection
			Syncope
Demographics	Body measures	Observation	Birth height
			Birth height (percentile)
			Body mass index
			Body mass index (percentile)
			Head circumference
			Head circumference (percentile)
Imaging	Echocardiography	Procedure, Imaging Study	Echocardiography
	PET-CT	Procedure, Imaging Study	Positron emission tomography with computed tomography
Immunization	Immunizations performed	Immunization	Viral vector vaccine
			mRNA vaccine
Laboratory values	Laboratory values	Observation	Alanine Aminotransferase
			Albumin
			Amylase
			Calprotectin
			Cells in CSF
			Complement C3
			Complement C4
			Creatine kinase
			Creatine kinase.MB

			Erythrocyte sedimentation rate
			Glucose in CSF
			Hematocrit
			IgG
			Interleukin 10
			Interleukin 2 Receptor Soluble
			Lactate in CSF
			Lipase
			Natural killer cell function
			Neutrophil cytoplasmic Ab
			Nuclear Ab
			Protein in CSF
			Prothrombin time (PT)
			SARS-CoV-2 RT in stool
			SARS-CoV-2 RT in urine
			Sodium
			Triglyceride
			Urea
Medical history	Chronic Hematologic Diseases	Condition	Blood coagulation disorder
			Glucose-6-phosphate dehydrogenase deficiency anemia
			Hemolytic anemia
			Iron deficiency anemia
			Myelodysplastic syndrome
			Neutropenic disorder where Clinical course = Chronic
			Sickle cell-hemoglobin SS disease
			Thalassemia
	Chronic Kidney Diseases	Condition	Disorder of the urinary system where Occurrence = Congenital
			Kidney disease where Occurrence = Congenital
	Congenital Disease	Condition	Congenital Disease
	Gastrointestinal Diseases	Condition	Allergy to cow's milk protein
			Celiac disease
Chronic constipation			
Disorder of bile duct			
Disorder of gastrointestinal tract			
Medical History Stem Cells Transplant	Condition	History of bone marrow transplant	
		History of peripheral stem cell transplant	
Medication	Medication	MedicationStatement	Blood product
			Bronchodilator
			Inotropic agent
			Medicinal product acting as antibacterial agent
			Medicinal product acting as hemostatic
			Product containing anakinra
			Product containing aspirin
			Product containing human immunoglobulin
Product containing nitric oxide			

			Product containing tocilizumab
			Vasopressor
		MedicationStatement, List	Alkylating agent
			Anti-CD20 antibody
			Anti-CD3 antibody
			Anti-CD3/CD19 antibody
			Anti-CD52 antibody
			Antimetabolite
			B cell activating factor inhibitor
			Calcineurin inhibitor
			Cytotoxic T-lymphocyte-associated protein 4 inhibitor
			Equine antithymocyte immunoglobulin
			Immunoglobulin E
			Integrin inhibitor
			Interferon
			Interleukin 1 receptor antagonist
			Interleukin 17 receptor antagonist
			Interleukin 2 receptor antagonist
			Interleukin 6 receptor antagonist
			Janus kinase inhibitor
			Mammalian target of rapamycin-Kinase inhibitor
			Protein-tyrosine kinase inhibitor
			Sphingosine analogue
			Steroid
			Tumor necrosis factor alpha inhibitor
			interleukin 23 receptor antagonist
Symptoms	COVID-19 Symptoms	Condition	Delirium
			Eruption of skin
			Large liver
			Myoclonus
			Pain in throat
			Palmar erythema
			Raspberry tongue
			Splenomegaly
			Swallowing painful
Therapy	Hospitalization	Observation	Intensive care treatment duration
			Total length of stay
	Thoracic Drainage	Procedure	Thoracic Drainage

551 *Table S 2 Data items in the pediatrics extension module extending the GECCO core dataset. Shown are*
552 *the data elements and the FHIR resource they have been mapped to, as well as the items for each data*
553 *element (i.e., different response options).*

554

555 GECCO Cardiology extension module

Category	Data Element	FHIR Resource	Item
Anamnesis	Chronic cardiologic diseases	Condition	Atrial fibrillation
			Atrial flutter
			Cardiomyopathy
			Congenital heart disease
			Heart failure
			History of coronary artery bypass grafting
COVID-19-related complications	Cardiologic complications of COVID-19	Condition	Bacterial respiratory infection
			Cardiogenic shock
			Complete atrioventricular block
			Myocarditis
			Pericardial effusion
			Ventricular fibrillation
			Viral disease
Echocardiography	Echocardiography findings	Observation	Abscess of heart
			Aortic valve regurgitation
			Aortic valve stenosis
			Heart valve disorder
			Left Ventricular Ejection Fraction
			Left ventricular hypertrophy
			Left ventricular wall motion abnormality
			Mitral valve regurgitation
			Mitral valve stenosis
			Paradoxical cardiac wall motion
			Pericardial effusion
			Pulmonic valve regurgitation
			Pulmonic valve stenosis
			Right ventricular hypertrophy
			Thrombosis
			Tricuspid annular plane systolic excursion (TAPSE)
			Tricuspid valve regurgitation
			Tricuspid valve stenosis
	Vegetation of heart		
	Ventricular hypertrophy		
	Echocardiography procedure	Procedure	Date
			Echocardiography
			Type of echocardiography
Electrocardiography	Electrocardiography findings	Observation	Atrial ectopics
			Atrioventricular Block
			Bundle Branch Block
			Inverted T wave
			Low QRS voltages
			Premature ventricular contractions
			QRS Axis

			QRS Interval
			QT Interval
			ST Interval
			Sinus rhythm
	Electrocardiography procedure	Procedure	12 lead electrocardiogram
			Date
Laboratory Values	Laboratory values	Observation	Troponin I
			Troponin T
Medication	Angiotensin receptor antagonist	MedicationStatement	Angiotensin Receptor Antagonist

556 *Table S 3 Data items in the cardiology extension module extending the GECCO core dataset. Shown are*
 557 *the data elements and the FHIR resource they have been mapped to, as well as the items for each data*
 558 *element (i.e., different response options).*

559

560